Market Cap 246.57M
Revenue (ttm) 0.00
Net Income (ttm) -63.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.12
Volume 1,693,400
Avg Vol 1,265,760
Day's Range N/A - N/A
Shares Out 54.19M
Stochastic %K 9%
Beta 1.13
Analysts Strong Sell
Price Target $19.71

Company Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based g...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
Zweagel91
Zweagel91 Mar. 21 at 8:22 AM
$ABEO very curious to see what will happen to the short % next week. Borrow rates en short shares availability definitely moving in the right direction. I don't see a squeeze happening next week after triple witching yesterday but i do hope we're going to trade based more on fundamentals from now on.
0 · Reply
azv134
azv134 Mar. 20 at 9:22 PM
THIS MARKET CRASH IS PERFECT TO MAKE THE FOLLOWING STOCKS MY CORE POSITIONS IN 2026 $ABEO $HROW $AQST $OCUL Aiming for ~ 15% allocation of my portfolio in each company.
0 · Reply
TimeForBio
TimeForBio Mar. 20 at 3:27 PM
$ABEO Let’s think about what Q2 may look like. In the Q3 call in November, management linked all 12 Z-POPs to the first 2 centers. Then, in the March Leerink call, they said: “With regard to order forms, we had communicated 12, and we are in the process of clearing those patients through.” We already know 2 patients were treated, and there will probably be 1 more in Q1. Also, management said the path from identified patient to treatment takes ~4–5 months. So if those 12 Z-POPs were already in place in November, it’s very likely the remaining 9 get treated in Q2. And that’s before adding possible contribution from the 3rd center, which may add another 1-2 patients in Q2. Q2 could be very strong. The Q1 call in May should make that clear.
1 · Reply
acm20
acm20 Mar. 20 at 3:02 PM
$ABEO Added 1,110/shrs btw $4.48 -$4.51
2 · Reply
Pharma3000
Pharma3000 Mar. 20 at 3:00 PM
$ABEO Lets go back to green!
0 · Reply
alexpitti
alexpitti Mar. 20 at 12:17 AM
$ABEO these gene therapies take time to launch, but production issued are moderating and patients are starting to get treated in March I've never really felt this way, but for the first time i do want the shorts to get ravaged
1 · Reply
myman1956
myman1956 Mar. 19 at 6:38 PM
$ABEO HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
0 · Reply
TimeForBio
TimeForBio Mar. 19 at 5:53 PM
$ABEO Some people here have unrealistically high expectations and don’t really understand what it takes to manage the commercialization phase. Listen, the QTCs operate independently. That means Abeona is basically waiting for them to send patients for treatment. The QTCs get paid by the payers and then pay Abeona. That’s exactly why it’s hard for the CEO to sound more confident about achieving profitability. It doesn’t depend only on Abeona. When you look at the full picture, you realize this may take some time, but eventually they’ll have 7+ active QTCs working much faster than they are now. With more than 100 identified patients, most of whom will likely need two treatments, and with broad payer coverage, the path forward looks very clear. The current valuation is ridiculous, especially when you consider how much cash this company has and how early it still is in commercialization. Stay patient and you’ll be rewarded. And by rewarded, I mean 3x–4x.
4 · Reply
Filvul
Filvul Mar. 19 at 4:18 PM
$ABEO The ~26–29% short float is genuine squeeze fuel, but it needs a fundamental or news catalyst, not just an expiration event, to ignite.
0 · Reply
Filvul
Filvul Mar. 19 at 4:10 PM
$ABEO we will have to wait until 2p27 for this to rise. This one has true meaning of longs...
0 · Reply
Latest News on ABEO
Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:11 PM EST - 4 months ago

Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call Transcript


Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:25 PM EDT - 7 months ago

Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript


Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript

May 16, 2025, 1:37 AM EDT - 11 months ago

Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript


US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 11 months ago

US FDA approves Abeona's skin disorder therapy


Pz-Cel Has Massive Potential For RDEB Patients

Apr 21, 2025, 10:00 AM EDT - 11 months ago

Pz-Cel Has Massive Potential For RDEB Patients


Zweagel91
Zweagel91 Mar. 21 at 8:22 AM
$ABEO very curious to see what will happen to the short % next week. Borrow rates en short shares availability definitely moving in the right direction. I don't see a squeeze happening next week after triple witching yesterday but i do hope we're going to trade based more on fundamentals from now on.
0 · Reply
azv134
azv134 Mar. 20 at 9:22 PM
THIS MARKET CRASH IS PERFECT TO MAKE THE FOLLOWING STOCKS MY CORE POSITIONS IN 2026 $ABEO $HROW $AQST $OCUL Aiming for ~ 15% allocation of my portfolio in each company.
0 · Reply
TimeForBio
TimeForBio Mar. 20 at 3:27 PM
$ABEO Let’s think about what Q2 may look like. In the Q3 call in November, management linked all 12 Z-POPs to the first 2 centers. Then, in the March Leerink call, they said: “With regard to order forms, we had communicated 12, and we are in the process of clearing those patients through.” We already know 2 patients were treated, and there will probably be 1 more in Q1. Also, management said the path from identified patient to treatment takes ~4–5 months. So if those 12 Z-POPs were already in place in November, it’s very likely the remaining 9 get treated in Q2. And that’s before adding possible contribution from the 3rd center, which may add another 1-2 patients in Q2. Q2 could be very strong. The Q1 call in May should make that clear.
1 · Reply
acm20
acm20 Mar. 20 at 3:02 PM
$ABEO Added 1,110/shrs btw $4.48 -$4.51
2 · Reply
Pharma3000
Pharma3000 Mar. 20 at 3:00 PM
$ABEO Lets go back to green!
0 · Reply
alexpitti
alexpitti Mar. 20 at 12:17 AM
$ABEO these gene therapies take time to launch, but production issued are moderating and patients are starting to get treated in March I've never really felt this way, but for the first time i do want the shorts to get ravaged
1 · Reply
myman1956
myman1956 Mar. 19 at 6:38 PM
$ABEO HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
0 · Reply
TimeForBio
TimeForBio Mar. 19 at 5:53 PM
$ABEO Some people here have unrealistically high expectations and don’t really understand what it takes to manage the commercialization phase. Listen, the QTCs operate independently. That means Abeona is basically waiting for them to send patients for treatment. The QTCs get paid by the payers and then pay Abeona. That’s exactly why it’s hard for the CEO to sound more confident about achieving profitability. It doesn’t depend only on Abeona. When you look at the full picture, you realize this may take some time, but eventually they’ll have 7+ active QTCs working much faster than they are now. With more than 100 identified patients, most of whom will likely need two treatments, and with broad payer coverage, the path forward looks very clear. The current valuation is ridiculous, especially when you consider how much cash this company has and how early it still is in commercialization. Stay patient and you’ll be rewarded. And by rewarded, I mean 3x–4x.
4 · Reply
Filvul
Filvul Mar. 19 at 4:18 PM
$ABEO The ~26–29% short float is genuine squeeze fuel, but it needs a fundamental or news catalyst, not just an expiration event, to ignite.
0 · Reply
Filvul
Filvul Mar. 19 at 4:10 PM
$ABEO we will have to wait until 2p27 for this to rise. This one has true meaning of longs...
0 · Reply
alcacer123
alcacer123 Mar. 19 at 12:46 PM
$ABEO Abeona Therapeutics is currently a commercialization company. It has a significant advantage: it doesn't need a large number of patients or treatments to be highly profitable. What it needs is to focus on its core mission: providing Zevaskyn treatments. For 20 years, it has been striving to achieve what it must now accomplish. The goal this year is to reach a stable intake of 10 patients per month. This alone will transform it into a highly profitable company. It's a matter of working diligently, investing what is necessary, and moving forward. It's that simple, yet that challenging. It's going to be a great year.
0 · Reply
JBio
JBio Mar. 19 at 10:55 AM
$ABEO "Just if you can comment on, based on the demand ramp that you're seeing, how confident are you in achieving profitability first half this year?" Vish Seshadri CEO "We believe that we have a pretty good chance of achieving profitability. I think profitability, if you define it as an entire company level, you know, profitability, I think there's numerous factors, as you already know. We've mentioned that anything north of three patients a month takes us to the profitable zone, which is, you know, $100 million, give or take, is about the company burn in a given year, right? If you use your gross and net calculations, 3.5 or more per month is taking us to the profitable zone. I think this is a very achievable target."
1 · Reply
TragicRain
TragicRain Mar. 18 at 7:02 PM
$ABEO - Just buying 100 shares at a time when I can under $5 -
0 · Reply
alexpitti
alexpitti Mar. 18 at 6:47 PM
sometimes these stocks have a little bump in the road and fall. and then some macro issue just exacerbates the selling to no end $DCTH $ABEO $STXS
1 · Reply
Longboardsoul
Longboardsoul Mar. 18 at 4:52 PM
$ABEO hopefully Vish the fish can dig into his pockets and throw some rupees down to buy a couple shares..
2 · Reply
Groggok
Groggok Mar. 18 at 4:52 PM
$ABEO OUTPERFORM - $22 PT
0 · Reply
mcube1820
mcube1820 Mar. 18 at 4:35 PM
$ABEO with cash taken into account, this is selling for less than $1.00 @share
1 · Reply
acm20
acm20 Mar. 18 at 3:37 PM
$ABEO Volume supporting the current push upwards from a low of $4.36 earlier.
0 · Reply
ZacksSCR
ZacksSCR Mar. 18 at 3:12 PM
$ABEO: Momentum Building for Zevaskyn® https://buff.ly/4Hy0wDM
0 · Reply
acm20
acm20 Mar. 18 at 3:10 PM
$ABEO Funds now available to add. Anticipating a dip closer to $4 in the near future imo.
1 · Reply
Cautiousamphybian
Cautiousamphybian Mar. 18 at 2:53 PM
$ABEO Put/call ratio for 20th March triple witching is currently sitting at 0.20 with 32k call contracts due to expire and 6.2k call contracts due to expire. Roughly 14k contracts currently in the money with the rest due to expire worthless meaning the MM's don't have to cover them. 11k contracts sit at $4 which is why there's so much pressure to push the price down before Friday. Once we move past triple witching there's not the same obligation by MM's to keep the price pinned and the price should start to trade on fundamentals. You can verify this information for yourselves on Yahoo finance or many other options reporting sites.
1 · Reply
fatpie68
fatpie68 Mar. 18 at 2:48 PM
I saw the same P/S ratio and right now, FinViz has $ABEO at 41.85 which makes sense because they have so little sales - the denominator will go up once they secure more sales (which is what I'm betting on) and that ratio will come down into the industry average.
1 · Reply